Aptose Biosciences details new Reg FD press release

Aptose Biosciences Inc. filed a current report to note that on August 22, 2025 it issued a press release, which is attached as Exhibit 99.1.

Accepted by SEC EDGAR 08/22/2025 - 05:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Aptose Biosciences Inc. filed a current report to note that on August 22, 2025 it issued a press release, which is attached as Exhibit 99.1. The company states that this press release is being furnished under a Regulation FD disclosure item and will not be treated as filed for liability purposes under the Securities Exchange Act or automatically incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aptose Biosciences Inc. (APTO) disclose in this 8-K?

Aptose Biosciences Inc. disclosed that it issued a press release on August 22, 2025, which is attached as Exhibit 99.1 to the report under a Regulation FD disclosure item.

What is included as Exhibit 99.1 in Aptose Biosciences' 8-K?

Exhibit 99.1 contains a press release dated August 22, 2025 issued by Aptose Biosciences Inc.

How is the press release in this Aptose (APTO) 8-K treated under securities laws?

The press release furnished as Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated into other filings under the Securities Act or Exchange Act unless specifically referenced.

Which item of Form 8-K does Aptose Biosciences use for this disclosure?

Aptose Biosciences uses Item 7.01, Regulation FD Disclosure, to furnish the press release to the market.

Who signed this Aptose Biosciences (APTO) 8-K?

The 8-K was signed on behalf of Aptose Biosciences Inc. by William G. Rice, Ph.D., the company’s Chairman, President, and Chief Executive Officer.

Does this Aptose Biosciences 8-K contain financial statements?

No. Under Item 9.01, Aptose lists only the press release as Exhibit 99.1 and an Inline XBRL cover page file as Exhibit 104; no separate financial statements are provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

False000088236100008823612025-08-222025-08-22iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 22, 2025

_______________________________

Aptose Biosciences Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Canada	001-32001	98-1136802
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

66 Wellington Street West, Suite 5300

TD Bank Tower, Box 48

Toronto, Ontario M5K 1E6
Canada

(Address of Principal Executive Offices) (Zip Code)

(647) 479-9828

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On August 22, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release dated August 22, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aptose Biosciences Inc.
Date: August 22, 2025	By:	/s/ William G. Rice, Ph.D.
		William G. Rice, Ph.D.
		Chairman, President, and Chief Executive Officer